Learn more about  clinical trials  at Roswell Park Cancer Institute.

Roswell Park Cancer Institute (RPCI) was founded in 1898 and is the nation's first cancer research, treatment, and education center. It is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. This designation means that a cancer center's combined research, treatment, prevention and educational programs have weathered extensive peer review, met rigorous national standards, and made fundamental contributions to reducing the cancer burden. RPCI is also credited with initiating the world's first chemotherapy studies and pioneering the prostate-specific antigen (PSA) test.

Specialized programs at RPCI have been established for blood and marrow transplantation, neuro-oncology, pigmented tumors, genetic counseling and testing, long-term survivors of childhood cancer, pain management, photodynamic therapy, robotics, and minimally invasive surgery (Gamma Knife, brachytherapy, RFA, VATS, etc). Specialized treatments include high-priority protocols and new therapeutic regimens based on the recent advances in biochemical pharmacology, genetics, immunology, and biological response modifiers.

RPCI focuses on prevention within their Cancer Prevention Program, which has three major themes: Risk Assessment & Biomarkers, Tobacco Control Research, and Nutrition & Chemical Intervention.

RPCI's Center for Pharmacology & Therapeutics is capable of taking drug development from conception stage through clinical trials and FDA approval within the confines of a single institution. Learn more about clinical trials at Roswell Park Cancer Institute.